source
- FDA launches Neuroscience Advancement and Innovation Nexus to boost brain disorder drug developmentThe U.S. Food and Drug Administration announced a new program called the Neuroscience Advancement and Innovation Nexus (NAIN) aimed at accelerating the development of medical products for brain and…
- FDA accepts new submission for Biohaven’s Vyglxia, opening path to approvalBiohaven announced that the FDA has accepted a refreshed application for its rare disease drug Vyglxia, which targets a nerve‑damaging disorder. Vyglxia is being developed for spinocerebellar atax…